ADVANCED NANOTHERAPEUTICS IN MULTIPLE SCLEROSIS TREATMENT: FROM BLOOD-BRAIN BARRIER CROSSING TO REMYELINATION ENHANCEMENT
DOI:
https://doi.org/10.22159/ijap.2026v18i1.56603Keywords:
Nanotechnology, Multiple sclerosis, Drug delivery, Blood-brain barrier, Neuroprotection, RemyelinationAbstract
Multiple sclerosis (MS) is a debilitating autoimmune demyelinating disorder characterised by chronic inflammation, progressive neurodegeneration, and failed remyelination. Current disease-modifying therapies remain limited by poor blood-brain barrier (BBB) penetration, systemic toxicity, and inadequate targeting of pathological processes. This review comprehensively analyses the role of nanotechnology in overcoming these therapeutic hurdles, examining cutting-edge platforms that address BBB crossing, immunomodulation, and remyelination enhancement in MS treatment.
Three primary nanotechnology platforms demonstrate exceptional therapeutic potential: Gold nanocrystals (CNM-Au8) showing remarkable remyelination activity through energy metabolism enhancement, currently in Phase 2 clinical trials with demonstrated oral bioavailability and BBB penetration; PLGA nanoparticles loaded with myelin antigens inducing robust antigen-specific immune tolerance via tolerogenic immune-modifying mechanisms, preventing disease progression in preclinical models; and Extracellular vesicles providing natural BBB crossing capability with superior immunomodulatory and remyelination-promoting effects through microRNA and growth factor delivery. Additional promising platforms include mannosylated liposomes for targeted antigen delivery, solid lipid nanoparticles for enhanced brain bioavailability, and phosphorus-based dendrimers for precision immunomodulation. These approaches demonstrate significant improvements in motor function, reduced neuroinflammation, enhanced myelin repair, and induction of long-lasting immune tolerance.
Despite remarkable preclinical success and early clinical validation, challenges in manufacturing scalability, regulatory translation, and long-term safety profiles remain. Future efforts must focus on clinical translation through optimised targeting designs, standardisedcharacterisation protocols, and comprehensive toxicity studies to realise the transformative potential of precision nanomedicine in MS therapy.
References
1. Mohammed EM. Understanding multiple sclerosis pathophysiology and current disease-modifying therapies: a review of unaddressed aspects. Front Biosci (Landmark Ed). 2024 Nov 19;29(11):386. doi: 10.31083/j.fbl2911386, PMID 39614433.
2. Oh J, Bar Or A. Emerging therapies to target CNS pathophysiology in multiple sclerosis. Nat Rev Neurol. 2022;18(8):466-75. doi: 10.1038/s41582-022-00675-0, PMID 35697862.
3. Lorenzut S, Negro ID, Pauletto G, Verriello L, Spadea L, Salati C. Exploring the pathophysiology, diagnosis and treatment options of multiple sclerosis. J Integr Neurosci. 2025;24(1):25081. doi: 10.31083/JIN25081, PMID 39862004.
4. Yong HY, Yong VW. Mechanism based criteria to improve therapeutic outcomes in progressive multiple sclerosis. Nat Rev Neurol. 2022;18(1):40-55. doi: 10.1038/s41582-021-00581-x, PMID 34732831.
5. Haki M, Al Biati HA, Al Tameemi ZS, Ali IS, Al Hussaniy HA. Review of multiple sclerosis: epidemiology etiology pathophysiology and treatment. Medicine. 2024;103(8):e37297. doi: 10.1097/MD.0000000000037297, PMID 38394496.
6. Balasa R, Barcutean L, Mosora O, Manu D. Reviewing the significance of blood–brain barrier disruption in multiple sclerosis pathology and treatment. Int J Mol Sci. 2021;22(16):8370. doi: 10.3390/ijms22168370, PMID 34445097.
7. Piehl F. Current and emerging disease modulatory therapies and treatment targets for multiple sclerosis. J Intern Med. 2021 Jun;289(6):771-91. doi: 10.1111/joim.13215, PMID 33258193.
8. Panghal A, Flora SJ. Nano-based approaches for the treatment of neuro-immunological disorders: a special emphasis on multiple sclerosis. Discov Nano. 2024 Oct 28;19(1):171. doi: 10.1186/s11671-024-04135-0, PMID 39466516.
9. Damavandi AR, Mirmosayyeb O, Ebrahimi N, Zalpoor H, Khalilian P, Yahiazadeh S. Advances in nanotechnology versus stem cell therapy for the theranostics of multiple sclerosis disease. Appl Nanosci. 2023 Jun;13(6):4043-73. doi: 10.1007/s13204-022-02698-x.
10. Jan Z, Mollazadeh S, Abnous K, Taghdisi SM, Danesh A, Ramezani M. Targeted delivery platforms for the treatment of multiple sclerosis. Mol Pharm. 2022 Jul 4;19(7):1952-76. doi: 10.1021/acs.molpharmaceut.1c00892, PMID 35501974.
11. Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017;264:306-32. doi: 10.1016/j.jconrel.2017.08.033, PMID 28844756.
12. Mohapatra R, Giri D, Vijayakumar D, Alagendran S, Saavedra DG, Jena JP. Nanomaterials in biomedical applications: a review. J Adv Biol Biotechnol. 2025 Apr 5;28(3):996-1009. doi: 10.9734/jabb/2025/v28i32157.
13. Thi TT, Suys EJ, Lee JS, Nguyen DH, Park KD, Truong NP. Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines. Vaccines. 2021 Apr 8;9(4):359. doi: 10.3390/vaccines9040359, PMID 33918072.
14. Wang Y, Li P, Kong L. Chitosan modified PLGA nanoparticles with versatile surface for improved drug delivery. AAPS PharmSciTech. 2013 Jun;14(2):585-92. doi: 10.1208/s12249-013-9943-3, PMID 23463262.
15. Burlec AF, Corciova A, Boev M, Batir Marin D, Mircea C, Cioanca O. Current overview of metal nanoparticles synthesis, characterization and biomedical applications with a focus on silver and gold nanoparticles. Pharmaceuticals (Basel). 2023 Oct 4;16(10):1410. doi: 10.3390/ph16101410, PMID 37895881.
16. Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid nanoparticles as carriers for bioactive delivery. Front Chem. 2021 Apr 23;9:580118. doi: 10.3389/fchem.2021.580118, PMID 33981670.
17. Belousov AN. Efficiency of nanoparticles (micromage-B) in the complex treatment of multiple sclerosis. Clin Res Clin Rep. 2023;2(2):1-8. doi: 10.31579/2835-8325/010.
18. Martinelli C, Pucci C, Battaglini M, Marino A, Ciofani G. Antioxidants and nanotechnology: promises and limits of potentially disruptive approaches in the treatment of central nervous system diseases. Adv Healthc Mater. 2020 Feb;9(3):e1901589. doi: 10.1002/adhm.201901589, PMID 31854132.
19. Jimenez A, Estudillo E, Guzman Ruiz MA, Herrera Mundo N, Victoria Acosta G, Cortes Malagon EM. Nanotechnology to overcome blood brain barrier permeability and damage in neurodegenerative diseases. Pharmaceutics. 2025 Feb 20;17(3):281. doi: 10.3390/pharmaceutics17030281, PMID 40142945.
20. Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation and drug delivery. Signal Transduct Target Ther. 2023 May 25;8(1):217. doi: 10.1038/s41392-023-01481-w, PMID 37231000.
21. Gonzalez Lorenzo M, Ridley B, Minozzi S, Del Giovane C, Peryer G, Piggott T. Immunomodulators and immunosuppressants for relapsing remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2024;1(1):CD011381. doi: 10.1002/14651858.CD011381.pub3, PMID 38174776.
22. Luo Q, Yang J, Yang M, Wang Y, Liu Y, Liu J. Utilization of nanotechnology to surmount the blood brain barrier in disorders of the central nervous system. Mater Today Bio. 2025 Jan 4;31:101457. doi: 10.1016/j.mtbio.2025.101457, PMID 39896289.
23. Liu J, Wang T, Dong J, Lu Y. The blood brain barriers: novel nanocarriers for central nervous system diseases. J Nanobiotechnology. 2025 Feb 26;23(1):146. doi: 10.1186/s12951-025-03247-8, PMID 40011926.
24. Xie J, Shen Z, Anraku Y, Kataoka K, Chen X. Nanomaterial-based blood brain-barrier (BBB) crossing strategies. Biomaterials. 2019 Dec 1;224:119491. doi: 10.1016/j.biomaterials.2019.119491, PMID 31546096.
25. Han L. Modulation of the blood brain barrier for drug delivery to brain. Pharmaceutics. 2021;13(12):2024. doi: 10.3390/pharmaceutics13122024, PMID 34959306.
26. Bai X, Smith ZL, Wang Y, Butterworth S, Tirella A. Sustained drug release from smart nanoparticles in cancer therapy: a comprehensive review. Micromachines. 2022 Sep 28;13(10):1623. doi: 10.3390/mi13101623, PMID 36295976.
27. Sharma A, Sharma N, Singh S, Dua K. Review on theranostic and neuroprotective applications of nanotechnology in multiple sclerosis. J Drug Deliv Sci Technol. 2023 Mar 1;81:104220. doi: 10.1016/j.jddst.2023.104220.
28. Ojha S, Kumar B. A review on nanotechnology based innovations in diagnosis and treatment of multiple sclerosis. J Cell Immunother. 2018 Dec 1;4(2):56-64. doi: 10.1016/j.jocit.2017.12.001.
29. Gharagozloo M, Bannon R, Calabresi PA. Breaking the barriers to remyelination in multiple sclerosis. Curr Opin Pharmacol. 2022 Apr 1;63:102194. doi: 10.1016/j.coph.2022.102194, PMID 35255453.
30. Maheshwari S, Verma A, Singh A, Wasim R, Shariq M, Akhtar J. Emergence of nanomaterials in the management of multiple sclerosis. In: Ansari MM, Suresh AK, Akhtar N, editors. Emergence of sustainable biomaterials in tackling inflammatory diseases Smart. Singapore: Springer; 2025. p. 323-40. doi: 10.1007/978-981-96-2112-5_12.
31. Takei EK. The use of nanoparticles in the diagnosis and treatment of multiple sclerosis: a scoping review. STEM Fellowship J. 2024 May 23;10(1):59-73. doi: 10.17975/sfj-2024-005.
32. Nuzzo D, Picone P. Multiple sclerosis: focus on extracellular and artificial vesicles nanoparticles as potential therapeutic approaches. Int J Mol Sci. 2021;22(16):8866. doi: 10.3390/ijms22168866, PMID 34445572.
33. Bilorosiuk M, Steinman L, Koppisetti S, Hariri R, Leibovitch EC, Jacobson S. Nanomedicine in demyelinating disease application to diagnosis and therapy in multiple sclerosis. In: Kateb B, Heiss JD, Yu JS, Hsieh M, editors. The Textbook of Nanoneuroscience and Nanoneurosurgery. Berlin: Springer Nature; 2024 Nov 14. p. 477-96. doi: 10.1007/978-3-030-80662-0_29.
34. Tarannum S, Jain K. Drug delivery strategies in multiple sclerosis huntington’s disease and other neurodegenerative diseases. In: Mishra A, Kulhari H, editors. Drug delivery strategies in neurological disorders: challenges and opportunities. Singapore: Springer; 2023. p. 375-403. doi: 10.1007/978-981-99-6807-7_16.
35. El Say KM, El Sawy HS. Polymeric nanoparticles: promising platform for drug delivery. Int J Pharm. 2017 Aug 7;528(1-2):675-91. doi: 10.1016/j.ijpharm.2017.06.052, PMID 28629982.
36. Osorio Querejeta I, Carregal Romero S, Ayerdi Izquierdo A, Mager I, A NL, Wood M. MiR-219a-5p enriched extracellular vesicles induce OPC differentiation and EAE improvement more efficiently than liposomes and polymeric nanoparticles. Pharmaceutics. 2020 Feb 21;12(2):186. doi: 10.3390/pharmaceutics12020186, PMID 32098213.
37. Osorio Querejeta I, Carregal Romero S, Ayerdi Izquierdo A, Mager I, A NL, Wood M. MiR-219a-5p enriched extracellular vesicles induce OPC differentiation and EAE improvement more efficiently than liposomes and polymeric nanoparticles. Pharmaceutics. 2020;12(2):186. doi: 10.3390/pharmaceutics12020186, PMID 32098213.
38. Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: a review. Pharmaceutics. 2020;12(3):288. doi: 10.3390/pharmaceutics12030288, PMID 32210127.
39. Cappellano G, Comi C, Chiocchetti A, Dianzani U. Exploiting PLGA-based biocompatible nanoparticles for next-generation tolerogenic vaccines against autoimmune disease. Int J Mol Sci. 2019;20(1):204. doi: 10.3390/ijms20010204, PMID 30626016.
40. Manna S, Banerjee S, De A, Banerjee S, Das S, Rakshit P. Therapeutic and diagnostic implications of carbon dot: an advancement in the avenue towards cancer diabetes and neurodegenerative disorders. Pharm Nanotechnol. 2024 Sep 27. doi: 10.2174/0122117385314533240824090949, PMID 39350419.
41. Zierfuss B, Larochelle C, Prat A. Blood brain barrier dysfunction in multiple sclerosis: causes consequences and potential effects of therapies. Lancet Neurol. 2024 Jan 1;23(1):95-109. doi: 10.1016/S1474-4422(23)00377-0, PMID 38101906.
42. Amoriello R, Memo C, Ballerini L, Ballerini C. The brain cytokine orchestra in multiple sclerosis: from neuroinflammation to synaptopathology. Mol Brain. 2024;17(1):4. doi: 10.1186/s13041-024-01077-7, PMID 38263055.
43. Zhang S, Yang Y, LV X, Zhou X, Zhao W, Meng L. Exosome cargo in neurodegenerative diseases: leveraging their intercellular communication capabilities for biomarker discovery and therapeutic delivery. Brain Sci. 2024 Oct 23;14(11):1049. doi: 10.3390/brainsci14111049, PMID 39595812.
44. Kulkarni M, Patel K, Patel A, Patel S, Desai J, Patel M. Nanomaterials as drug delivery agents for overcoming the blood–brain barrier: a comprehensive review. ADMET DMPK. 2024 Feb 13;12(1):63-105. doi: 10.5599/admet.2043, PMID 38560713.
45. Zhang S, Yang Y, LV X, Zhou X, Zhao W, Meng L. Exosome cargo in neurodegenerative diseases: leveraging their intercellular communication capabilities for biomarker discovery and therapeutic delivery. Brain Sci. 2024 Oct 23;14(11):1049. doi: 10.3390/brainsci14111049, PMID 39595812.
46. Mahmoudi M, Sahraian MA, Shokrgozar MA, Laurent S. Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of multiple sclerosis. ACS Chem Neurosci. 2011 Mar 16;2(3):118-40. doi: 10.1021/cn100100e, PMID 22778862.
47. Rocca MA, Preziosa P, Barkhof F, Brownlee W, Calabrese M, De Stefano N. Current and future role of MRI in the diagnosis and prognosis of multiple sclerosis. Lancet Reg Health Eur. 2024 Sep 1;44:100978. doi: 10.1016/j.lanepe.2024.100978, PMID 39444702.
48. Zhang R, Kiessling F, Lammers T, Pallares RM. Clinical translation of gold nanoparticles. Drug Deliv Transl Res. 2023;13(2):378-85. doi: 10.1007/s13346-022-01232-4, PMID 36045273.
49. Phan NM, Nguyen TL, Shin H, Trinh TA, Kim J. ROS-scavenging lignin-based tolerogenic nanoparticle vaccine for treatment of multiple sclerosis. ACS Nano. 2023 Dec 5;17(24):24696-709. doi: 10.1021/acsnano.3c04497, PMID 38051295.
50. Collorone S, Coll L, Lorenzi M, Llado X, Sastre Garriga J, Tintore M. Artificial intelligence applied to MRI data to tackle key challenges in multiple sclerosis. Mult Scler. 2024 Jun;30(7):767-84. doi: 10.1177/13524585241249422, PMID 38738527.
51. Ghosh S, Bhatti GK, Sharma PK, Kandimalla R, Mastana SS, Bhatti JS. Potential of nano-engineered stem cells in the treatment of multiple sclerosis: a comprehensive review. Cell Mol Neurobiol. 2023;44(1):6. doi: 10.1007/s10571-023-01434-5, PMID 38104307.
52. Al Sayadi GM, Verma A, Choudhary Y, Sandal P, Patel P, Singh D. Solid lipid nanoparticles (SLNs): advancements in modification strategies toward drug delivery vehicle. Pharm Nanotechnol. 2023 Apr 1;11(2):138-54. doi: 10.2174/2211738511666221026163303, PMID 36305142.
53. Greco G, Sarpietro MG. Liposome assisted drug delivery in the treatment of multiple sclerosis. Molecules. 2024 Oct 3;29(19):4689. doi: 10.3390/molecules29194689, PMID 39407617.
54. Juhairiyah F, De Lange EC. Understanding drug delivery to the brain using liposome-based strategies: studies that provide mechanistic insights are essential. AAPS J. 2021 Oct 28;23(6):114. doi: 10.1208/s12248-021-00648-z, PMID 34713363.
55. Zhao Y, Zhang J, Cheng X, Huang W, Shen S, Wu S. Targeting L-selectin lymphocytes to deliver immunosuppressive drug in lymph nodes for durable multiple sclerosis treatment. Adv Sci (Weinh). 2023 Jul;10(20):e2300738. doi: 10.1002/advs.202300738, PMID 37170724, PMCID PMC10369270.
56. Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R. Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB. Pharmaceutics. 2021 Jul 31;13(8):1183. doi: 10.3390/pharmaceutics13081183, PMID 34452143.
57. Bove RM, Green AJ. Remyelinating pharmacotherapies in multiple sclerosis. Neurotherapeutics. 2017 Oct 1;14(4):894-904. doi: 10.1007/s13311-017-0577-0, PMID 28948533.
58. Li PY, Bearoff F, Zhu P, Fan Z, Zhu Y, Fan M. PEGylation enables subcutaneously administered nanoparticles to induce antigen-specific immune tolerance. J Control Release. 2021 Mar 10;331:164-75. doi: 10.1016/j.jconrel.2021.01.013, PMID 33450320.
59. Agrawal M, Saraf S, Saraf S, Dubey SK, Puri A, Patel RJ. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. J Control Release. 2020;321:372-415. doi: 10.1016/j.jconrel.2020.02.020, PMID 32061621.
60. Jiao Y, Yang L, Wang R, Song G, Fu J, Wang J. Drug delivery across the blood–brain barrier: a new strategy for the treatment of neurological diseases. Pharmaceutics. 2024 Dec 19;16(12):1611. doi: 10.3390/pharmaceutics16121611, PMID 39771589.
61. Niu X, Chen J, Gao J. Nanocarriers as a powerful vehicle to overcome blood–brain barrier in treating neurodegenerative diseases: focus on recent advances. Asian J Pharm Sci. 2019 Sep 1;14(5):480-96. doi: 10.1016/j.ajps.2018.09.005, PMID 32104476.
62. Bonferoni MC, Rossi S, Sandri G, Ferrari F, Gavini E, Rassu G. Nanoemulsions for “nose-to-brain” drug delivery. Pharmaceutics. 2019 Feb 17;11(2):84. doi: 10.3390/pharmaceutics11020084, PMID 30781585.
63. Kaye AD, Sala KR, Dethloff D, Norton M, Moss C, Plessala MJ. The evolving use of gold nanoparticles as a possible reversal agent for the symptoms of neurodegenerative diseases: a narrative review. Cureus. 2024 Jul 18;16(7):e64846. doi: 10.7759/cureus.64846, PMID 39156432.
64. Li Z, Bai R, Yi J, Zhou H, Xian J, Chen C. Designing smart iron oxide nanoparticles for MR imaging of tumors. Chem Biomed Imaging. 2023 Jul 24;1(4):315-39. doi: 10.1021/cbmi.3c00026, PMID 37501794.
65. Xu L, Wang YY, Huang J, Chen CY, Wang ZX, Xie H. Silver nanoparticles: synthesis medical applications and biosafety. Theranostics. 2020;10(20):8996-9031. doi: 10.7150/thno.45413, PMID 32802176.
66. Dehkordi AA, Mollazadeh S, Talaie A, Yazdimamaghani M. Engineering PAMAM dendrimers for optimized drug delivery. Nano Trends. 2025 Feb 16;9:100094. doi: 10.1016/j.nwnano.2025.100094.
67. Hayder M, Garzoni M, Bochicchio D, Caminade AM, Couderc F, Ong Meang V. Three dimensional directionality is a pivotal structural feature for the bioactivity of azabisphosphonate capped poly(PhosphorHydrazone) nanodrug dendrimers. Biomacromolecules. 2018 Feb 14;19(3):712-20. doi: 10.1021/acs.biomac.7b01398, PMID 29443507.
68. Garate Velez L, Quintana M. Carbon based nanomaterials: interactions with cells brain therapies and neural sensing. J Mater Sci: Mater Eng. 2025 Dec;20(1):1-23. doi: 10.1186/s40712-025-00236-5.
69. Haqqani AS, Belanger K, Stanimirovic DB. Receptor mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria. Front Drug Deliv. 2024 Mar 12;4:1360302. doi: 10.3389/fddev.2024.1360302, PMID 40836978.
70. Zhang W, Liu QY, Haqqani AS, Leclerc S, Liu Z, Fauteux F. Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels brain parenchyma and peripheral tissues of the mouse and the human. Fluids Barriers CNS. 2020 Jul 22;17(1):47. doi: 10.1186/s12987-020-00209-0, PMID 32698806.
71. Banks WA, Rhea EM, Reed MJ, Erickson MA. The penetration of therapeutics across the blood–brain barrier: classic case studies and clinical implications. Cell Rep Med. 2024 Nov 19;5(11):101760. doi: 10.1016/j.xcrm.2024.101760, PMID 39383873.
72. Pulgar VM. Transcytosis to cross the blood brain barrier new advancements and challenges. Front Neurosci. 2019 Jan 11;12:1019. doi: 10.3389/fnins.2018.01019, PMID 30686985.
73. Schreiner TG, Romanescu C, Popescu BO. The blood–brain barrier a key player in multiple sclerosis disease mechanisms. Biomolecules. 2022 Apr 2;12(4):538. doi: 10.3390/biom12040538, PMID 35454127.
74. Yang G, Van Kaer L. Therapeutic targeting of immune cell autophagy in multiple sclerosis: Russian roulette or silver bullet? Front Immunol. 2021 Aug 31;12:724108. doi: 10.3389/fimmu.2021.724108, PMID 34531871.
75. Mado H, Adamczyk Sowa M, Sowa P. Role of microglial cells in the pathophysiology of MS: synergistic or antagonistic? Int J Mol Sci. 2023 Jan 17;24(3):1861. doi: 10.3390/ijms24031861, PMID 36768183.
76. Vermersch P, Airas L, Berger T, Deisenhammer F, Grigoriadis N, Hartung HP. The role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors. Front Immunol. 2025;16:1495529. doi: 10.3389/fimmu.2025.1495529, PMID 40443664.
77. Tepavcevic V, Lubetzki C. Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more the merrier? Brain. 2022;145(12):4178-92. doi: 10.1093/brain/awac307, PMID 36093726.
78. Derdelinckx J, Cras P, Berneman ZN, Cools N. Antigen-specific treatment modalities in MS: the past the present and the future. Front Immunol. 2021;12:624685. doi: 10.3389/fimmu.2021.624685, PMID 33679769.
79. Nally FK, De Santi C, McCoy CE. Nanomodulation of macrophages in multiple sclerosis. Cells. 2019 Jun 5;8(6):543. doi: 10.3390/cells8060543, PMID 31195710.
80. Rittchen S, Boyd A, Burns A, Park J, Fahmy TM, Metcalfe S. Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF). Biomaterials. 2015 Jul 1;56:78-85. doi: 10.1016/j.biomaterials.2015.03.044, PMID 25934281.
81. Zveik O, Rechtman A, Ganz T, Vaknin Dembinsky A. The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cells. Mol Neurodegener. 2024 Jul 12;19(1):53. doi: 10.1186/s13024-024-00742-8, PMID 38997755.
82. Pulgar VM. Transcytosis to cross the blood brain barrier new advancements and challenges. Front Neurosci. 2019;12:1019. doi: 10.3389/fnins.2018.01019, PMID 30686985.
83. Horwitz DA, Bickerton S, Koss M, Fahmy TM, La Cava A. Suppression of murine lupus by CD4+ and CD8+ Treg Cells induced by T cell-targeted nanoparticles loaded with interleukin-2 and transforming growth factor β. Arthritis Rheumatol. 2019 Apr;71(4):632-40. doi: 10.1002/art.40773, PMID 30407752.
84. Horwitz DA, Bickerton S, La Cava A. Strategies to use nanoparticles to generate CD4 and CD8 regulatory T cells for the treatment of SLE and other autoimmune diseases. Front Immunol. 2021;12:681062. doi: 10.3389/fimmu.2021.681062, PMID 34211471.
85. Horwitz DA, Bickerton S, Koss M, Fahmy TM, La Cava A. Suppression of murine lupus by CD4+ and CD8+ Treg cells induced by T cell-targeted nanoparticles loaded with interleukin-2 and transforming growth factor β. Arthritis Rheumatol. 2019 Apr;71(4):632-40. doi: 10.1002/art.40773, PMID 30407752.
86. Chountoulesi M, Demetzos C. Promising nanotechnology approaches in treatment of autoimmune diseases of central nervous system. Brain Sci. 2020 Jun 2;10(6):338. doi: 10.3390/brainsci10060338, PMID 32498357.
87. Robinson AP, Zhang JZ, Titus HE, Karl M, Merzliakov M, Dorfman AR. Nanocatalytic activity of clean-surfaced faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis. Sci Rep. 2020;10(1):1936. doi: 10.1038/s41598-020-58709-w, PMID 32041968.
88. Vucic S, Menon P, Huynh W, Mahoney C, Ho KS, Hartford A. Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (Rescue-ALS study): a phase 2, randomised double-blind placebo-controlled trial and open label extension. E Clinical Medicine. 2023 Jun 1;60:102036. doi: 10.1016/j.eclinm.2023.102036, PMID 37396808.
89. Dong S. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine. 2008;3(3):311-21. doi: 10.2147/IJN.S2824.
90. La Mothe RA, Kolte PN, Vo T, Ferrari JD, Gelsinger TC, Wong J. Tolerogenic nanoparticles induce antigen-specific regulatory T cells and provide therapeutic efficacy and transferrable tolerance against experimental autoimmune encephalomyelitis. Front Immunol. 2018 Mar 2;9:281. doi: 10.3389/fimmu.2018.00281, PMID 29552007.
91. Park DJ, Yun WS, Kim WC, Park JE, Lee SH, Ha S. Improvement of stem cell-derived exosome release efficiency by surface-modified nanoparticles. J Nanobiotechnology. 2020 Dec 7;18(1):178. doi: 10.1186/s12951-020-00739-7, PMID 33287848.
92. Kenison JE, Stevens NA, Quintana FJ. Therapeutic induction of antigen-specific immune tolerance. Nat Rev Immunol. 2024 May;24(5):338-57. doi: 10.1038/s41577-023-00970-x, PMID 38086932.
93. Gholamzad M, Baharlooi H, Shafiee Ardestani MS, Seyedkhan Z, Azimi M. Prophylactic and therapeutic effects of MOG-conjugated PLGA nanoparticles in C57BL/6 mouse model of multiple sclerosis. Adv Pharm Bull. 2020 Jul 26;11(3):505-13. doi: 10.34172/apb.2021.058, PMID 34513625.
94. Tan F, Li X, Wang Z, Li J, Shahzad K, Zheng J. Clinical applications of stem cell-derived exosomes. Signal Transduct Target Ther. 2024 Jan 12;9(1):17. doi: 10.1038/s41392-023-01704-0, PMID 38212307.
95. Belousov AN, Belousova EY, Mysyk AV. A clinical case of the successful application of magnetite nanoparticles in the complex treatment of multiple sclerosis. J Recent Adv Nanomed & Nanotech. 2025;1(3):555565. doi: 10.19080/JRANN.2024.01.555566.
Published
How to Cite
Issue
Section
Copyright (c) 2026 NADEESH T., SUBHRAJYOTI DHARA, PRIYAM MANNA, PRITAM KAYAL
This work is licensed under a Creative Commons Attribution 4.0 International License.